Kim Kardashian West Found Morning Sickness Relief with Diclectin

Kim Kardashian West Found Morning Sickness Relief with Diclectin

Duchesnay encourages pregnant women to speak with their healthcare professionals about their condition and find relief with the only FDA and Health Canada-approved prescription treatment for morning sickness

Blainville, QC – July 20, 2015 – Duchesnay today expresses appreciation and well wishes to global celebrity Kim Kardashian West who announced on Instagram that she took Diclectin® (doxylamine succinate, pyridoxine hydrochloride) delayed-release tablets for the treatment of nausea and vomiting of pregnancy,1 more commonly known as morning sickness.

Kim revealed on July 19: "OMG. Have you heard about this? As you guys know my #morningsickness has been pretty bad. I tried changing things about my lifestyle, like my diet, but nothing helped, so I talked to my doctor. He prescribed me #Diclegis (Diclegis® is the same as Diclectin® in Canada), and I felt a lot better and most importantly, it's been studied and there was no increased risk to the baby. I'm so excited and happy with my results that I'm partnering with Duchesnay to raise awareness about treating morning sickness."

Diclectin® is for pregnant women like Kim Kardashian West, who do not find symptom relief from conservative management such as changes in diet. There is only one Health Canada-approved prescription medicine – Diclectin® – that has been available for 40 years and has been used by over 35 million pregnant women.

"We were aware that Kim Kardashian West has suffered from nausea and vomiting during her pregnancy with her first and second child and how it has interfered with her daily schedule, her work and her ability to spend time with her family," said Eric Gervais, Executive Vice-President of Duchesnay Canada. "We were pleased to hear Diclectin® is helping her feel better during her pregnancy. We applaud her for encouraging millions of pregnant women to talk to their healthcare professionals about safe and effective treatment options – including Diclectin®, the only FDA and Health Canada-approved treatment.

Diclectin®, made easy to identify by its pregnant woman on the pill, helps reduce symptoms of nausea and vomiting – is recommended as a first-line pharmacotherapy for morning sickness by the Society of Obstetricians and Gynaecologists of Canada (SOGC).2
For more information about Diclectin®, visit www.diclectin.com.

ABOUT NAUSEA AND VOMITING OF PREGNANCY (NVP)
Nausea and vomiting of pregnancy (NVP), commonly called morning sickness, affects up to 85 percent of pregnant women with symptoms ranging from nausea to severe vomiting and retching that can last throughout the day. Some pregnant women may experience symptoms throughout their pregnancy. If left untreated, symptoms can sometimes progress to a potentially more serious condition called hyperemesis gravidarum (HG), which may require hospitalization. NVP can have a dramatic impact on the emotional and physical well-being of the expectant woman and her family. NVP has also been shown to impose an economic burden on healthcare system and productivity lost.

ABOUT DICLECTIN®
Diclectin®, a delayed-release combination of doxylamine and vitamin B6, is the only antinauseant and antiemetic drug labelled and approved for use in pregnancy in USA and Canada. Its long and outstanding record of accomplishment of safety and efficacy has made Diclectin® the medicine of choice in Canada for over 40 years – the FDA's approval of Diclegis® (Diclegis® is the same as Diclectin® in Canada) allows the same in the United States. The FDA has assigned Diclegis® the highest safety rating possible which is Category A. Diclectin® and Diclegis® are manufactured in Canada, in Duchesnay's facility, for the international market, including the recent oversea expansion in Israel. Duchesnay is an important flagship of the Canadian pharmaceutical industry because of the economic role it plays in creating jobs due to international growth.

ABOUT DUCHESNAY
Duchesnay Inc. is a Canadian specialty pharmaceutical company dedicated to improve the health and quality of life of pregnant women by working at advancing maternal-fetal medicine to reduce the risk of birth defects and by developing safe and effective pharmacological solutions for use during pregnancy and breastfeeding. For more information, visit www.duchesnay.com.


For further information, please contact:
Ron Vaillancourt
Duchesnay
[email protected]
1 877 833-7734, ext. 280

or

Alida Alepian
Capital-Image for Duchesnay
[email protected]
514-739-1188, ext. 239

[1] Diclectin® (doxylamine succinate and pyridoxine hydrochloride) delayed-release tablets. Product monograph. Duchesnay, 2014.

[2] Society of Obstetricians and Gynaecologists of Canada. The Management of Nausea & Vomiting of Pregnancy. October 2002. Available at: http://sogc.org/wp-content/uploads/2013/01/120E-CPG-October2002.pdf. Accessed on July 9, 2015

Suggested Articles

After showing Nucala could cut the rates of flares for hypereosinophilic syndrome, GSK is planning regulatory filings in 2020.

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Both IL-17A inhibitors have rolled out data showing they work in non-radiographic axial spondyloarthritis.